Advertisement
Abstract

Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.

J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
Molecular Pharmacology December 1996, 50 (6) 1567-1580;

Article Information

vol. 50 no. 6 1567-1580
PubMed 
8967979
Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Published online December 1, 1996.

Author Information

  1. J E Leysen,
  2. W Gommeren,
  3. L Heylen,
  4. W H Luyten,
  5. I Van de Weyer,
  6. P Vanhoenacker,
  7. G Haegeman,
  8. A Schotte,
  9. P Van Gompel,
  10. R Wouters and
  11. A S Lesage
  1. Department of Biochemical Pharmacology, Janssen Research Foundation, Beerse, Belgium.

    Statistics from Altmetric.com

    Article usage

    Article usage: February 1999 to August 2022

    AbstractFullPdf
    Feb 1999200
    Mar 1999100
    May 1999200
    Jul 1999200
    Feb 2000200
    Mar 2000600
    Apr 2000600
    Jul 2000100
    Oct 2000100
    Nov 2000100
    Dec 2000101
    Jan 2001300
    Apr 2001100
    May 2001100
    Aug 2001200
    Sep 2001100
    Oct 2001100
    Feb 2002100
    Apr 2002100
    Jun 2002100
    Aug 2002200
    Sep 2002200
    Oct 2002100
    Nov 2002100
    Dec 2002100
    Mar 2003100
    May 2003100
    Jun 2003100
    Jul 2003500
    Aug 2003700
    Sep 2003100
    Oct 2003200
    Nov 20031000
    Dec 2003700
    Jan 2004700
    Feb 20041200
    Mar 20041300
    Apr 2004600
    May 20041000
    Jun 2004900
    Jul 20041500
    Aug 2004600
    Sep 2004500
    Oct 20041100
    Nov 20041000
    Dec 2004600
    Jan 2005900
    Feb 2005600
    Mar 2005600
    Apr 2005300
    May 2005300
    Jun 2005600
    Jul 2005200
    Aug 2005201
    Sep 2005502
    Oct 2005605
    Nov 20051203
    Dec 2005601
    Jan 2006200
    Feb 2006601
    Mar 2006404
    Apr 20061108
    May 2006700
    Jun 2006408
    Jul 2006400
    Aug 2006803
    Sep 2006500
    Oct 20066011
    Nov 2006706
    Dec 2006707
    Jan 2007302
    Feb 2007302
    Mar 2007202
    Apr 2007404
    May 2007301
    Jun 2007806
    Jul 2007604
    Aug 20071604
    Sep 2007503
    Oct 2007803
    Nov 20071402
    Dec 2007802
    Jan 2008202
    Feb 2008600
    Mar 20081003
    Apr 2008507
    May 20081203
    Jun 2008605
    Jul 2008603
    Aug 2008402
    Sep 2008701
    Oct 20081103
    Nov 20081103
    Dec 2008902
    Jan 20091602
    Feb 20091204
    Mar 2009908
    Apr 2009601
    May 2009601
    Jun 2009301
    Jul 20091204
    Aug 2009400
    Sep 20091403
    Oct 20091802
    Nov 20091206
    Dec 20091104
    Jan 20101304
    Feb 20101203
    Mar 20101605
    Apr 20101102
    May 20101302
    Jun 20101605
    Jul 20101007
    Aug 2010907
    Sep 2010801
    Oct 20108010
    Nov 2010601
    Dec 2010701
    Jan 20111402
    Feb 20111000
    Mar 20111103
    Apr 2011701
    May 2011700
    Jun 20111003
    Jul 20111101
    Aug 20112303
    Sep 2011605
    Oct 20111404
    Nov 20111202
    Dec 20111100
    Jan 2012500
    Feb 20121002
    Mar 20121202
    Apr 2012800
    May 2012700
    Jun 2012401
    Jul 20121402
    Aug 2012805
    Sep 2012400
    Oct 2012701
    Nov 2012606
    Dec 2012704
    Jan 20131203
    Feb 20131002
    Mar 2013704
    Apr 20132500
    May 20131405
    Jun 2013501
    Jul 2013300
    Aug 2013702
    Sep 2013601
    Oct 20131802
    Nov 2013401
    Jan 2014702
    Feb 2014202
    Mar 2014402
    Apr 2014401
    May 2014304
    Jun 2014605
    Jul 2014500
    Aug 2014400
    Sep 2014904
    Oct 20141302
    Nov 20141301
    Dec 2014401
    Jan 2015400
    Feb 2015701
    Mar 2015502
    Apr 2015203
    May 2015703
    Jun 20151101
    Jul 2015801
    Aug 2015300
    Sep 20152801
    Oct 2015301
    Nov 2015300
    Dec 2015001
    Jan 2016504
    Feb 20161104
    Mar 2016903
    Apr 2016603
    May 20161102
    Jun 2016302
    Jul 20161101
    Aug 20161105
    Sep 2016203
    Oct 20161401
    Nov 2016300
    Dec 2016501
    Jan 20172004
    Feb 20171302
    Mar 2017300
    Apr 20171004
    May 2017401
    Jun 20172703
    Jul 20171402
    Aug 20171201
    Sep 20174202
    Oct 20171503
    Nov 20171803
    Dec 20174703
    Jan 20181300
    Feb 20181700
    Mar 2018701
    Apr 20182103
    May 20182002
    Jun 20181200
    Jul 2018601
    Aug 20181701
    Sep 20181100
    Oct 20181301
    Nov 2018700
    Dec 2018400
    Jan 2019600
    Feb 2019700
    Mar 2019600
    Apr 2019401
    May 2019800
    Jun 20191403
    Jul 20191202
    Aug 20191700
    Sep 2019801
    Oct 20191401
    Nov 20191201
    Dec 20191100
    Jan 20201102
    Feb 2020802
    Mar 2020401
    Apr 20201003
    May 2020201
    Jun 20201000
    Jul 2020500
    Aug 2020700
    Sep 2020301
    Oct 2020700
    Nov 20201900
    Dec 2020900
    Jan 2021902
    Feb 2021801
    Mar 2021500
    Apr 20211000
    May 20212701
    Jun 2021300
    Jul 2021901
    Aug 20211100
    Sep 2021700
    Oct 20212000
    Nov 20213407
    Dec 20211700
    Jan 20222600
    Feb 20221200
    Mar 2022501
    Apr 2022901
    May 20221202
    Jun 20221201
    Jul 20221600
    Aug 2022200

    Back to top

    In this issue

    Download PDF
    Article Alerts
    Email Article
    Citation Tools

    Abstract

    Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.

    J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
    Molecular Pharmacology December 1, 1996, 50 (6) 1567-1580;
    del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

    Jump to section

    Related Articles

    Cited By...

    Similar Articles

    Advertisement